ALTS | tickerfilter.com

Fundamental analysis

33%

Profitability 35%

Dept financing 42%

Liquidity 31%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-6.63%

1 Month

-29.71%

3 Months

-60.52%

6 Months

-61.66%

1 Year

-86.55%

2 Year

-86.11%

Key data

Stock price

$0.86

P/E Ratio

N/A

DAY RANGE

$0.82 - $0.89

EPS

-$0.67

52 WEEK RANGE

$0.82 - $10.95

52 WEEK CHANGE

-$86.55

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

122.609 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-02-2025

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$3,469,262

AVERAGE 30 VOLUME

$3,365,994

Company detail

CEO: Antonios Isaac
Region: US
Website: janone.com
Employees: 170
IPO year: 1991

Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

JanOne Inc. focuses on identifying, acquiring, licensing, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease.

ALTS - ALT5 Sigma Corp